Why Biotech And Pharma Patents Survive IPR
When the America Invents Act of 2011 ushered in a number of new administrative procedures for challenging issued patents, the biotechnology and pharmaceutical industries at first seemed largely unconcerned. The new...To view the full article, register now.
Already a subscriber? Click here to view full article